title: [New synthetic and biologic treatments for spondylarthritis].
abstract: The only biological treatments recognized and reimbursed for spondylarthritis in Switzerland are anti TNF. Other effective agents in rheumatoid arthritis were found to be of little use in this indication. Fortunately, in recent years appeared biological molecules blocking cytokines involved in new pathways of inflammation in particular that of IL7. They have been very effective against psoriasis and have a high potential in psoriatic arthritis and spondylarthritis. In parallel, synthetic small molecules capable of modulating the production of intracellular cytokines begin to be marketed. They also are potentially active in the same rheumatic diseases. The purpose of this article is to review these new drugs, in particular to review the progress of their development and commercialization status.
authors.forename: Pascal
authors.initials: P
authors.lastname: Zufferey
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D015851:Interleukin-7 / Q000037:antagonists & inhibitors*; D053612:Janus Kinases / Q000037:antagonists & inhibitors*; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D025241:Spondylarthritis / Q000188:drug therapy* / Q000276:immunology; D013557:Switzerland; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D015851:Interleukin-7; D010726:Phosphodiesterase Inhibitors; D014409:Tumor Necrosis Factor-alpha; C571216:brodalumab; C549079:ixekizumab; D053612:Janus Kinases